Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | June 05, 2026 | June 09, 2026 |
| NORTHROP GRUMMAN CORP /DE/NOC · Entity 2963 | CVP & Chief Financial Officer | February 11, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.84 · Expires 2036-06-05 | Direct | 13,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 13,000 · Balance 13,000 F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
NORTHROP GRUMMAN CORP /DE/
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Performance Stock RightsSEC Table II · derivative / convertible security | Direct | 4,981 |
Reported balance
After 2026-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-11 · Grant · Acquired 4,981 · Balance 4,981 F1: Each Restricted Performance Stock Right ("RPSR") represents a contingent right to receive an equivalent number of shares of Issuer common stock, or, at the Issuer's election, cash or a combination of cash and Issuer common stock. The RPSRs vest if the applicable performance metric is satisfied for the relevant measurement period. Grants awarded pursuant to Rule 16b-3(d). F2: The RPSRs acquired include 4,981 unvested RPSRs granted under the 2024 Long-Term Incentive Stock Plan ("2024 LTISP) on 2/11/26 with a measurement period ending on 12/31/28. |
| Restricted Stock RightsSEC Table II · derivative / convertible security | Direct | 5,362 |
Reported balance
After 2026-02-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-11 · Grant · Acquired 5,362 · Balance 5,362 F3: Each Restricted Stock Right ("RSR") represents a contingent right to receive an equivalent number of shares in Issuer common stock, or, at the election of the Issuer's Compensation Committee, cash or a combination of cash and Issuer common stock. F4: The RSRs were granted under the 2024 LTISP on 2/11/26 and will vest on 2/12/29. F5: Total amount includes (i) 2,298 RSRs granted under the 2024 LTISP on 2/11/26 that will vest on 2/12/29; (ii) 1,532 RSRs granted under the 2024 LTISP on 2/11/26 that will vest on 2/11/27; and (iii) 1,532 RSRs granted under the 2024 LTISP on 2/11/26 that will vest on 2/11/28. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Performance Stock Right ("RPSR") represents a contingent right to receive an equivalent number of shares of Issuer common stock, or, at the Issuer's election, cash or a combination of cash and Issuer common stock. The RPSRs vest if the applicable performance metric is satisfied for the relevant measurement period. Grants awarded pursuant to Rule 16b-3(d).
F2: The RPSRs acquired include 4,981 unvested RPSRs granted under the 2024 Long-Term Incentive Stock Plan ("2024 LTISP) on 2/11/26 with a measurement period ending on 12/31/28.
F3: Each Restricted Stock Right ("RSR") represents a contingent right to receive an equivalent number of shares in Issuer common stock, or, at the election of the Issuer's Compensation Committee, cash or a combination of cash and Issuer common stock.
F4: The RSRs were granted under the 2024 LTISP on 2/11/26 and will vest on 2/12/29.
F5: Total amount includes (i) 2,298 RSRs granted under the 2024 LTISP on 2/11/26 that will vest on 2/12/29; (ii) 1,532 RSRs granted under the 2024 LTISP on 2/11/26 that will vest on 2/11/27; and (iii) 1,532 RSRs granted under the 2024 LTISP on 2/11/26 that will vest on 2/11/28.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Bioverativ Inc.
Report date March 08, 2018 · Filed March 08, 2018
Section 16 reporting ended · disclosed 2018-03-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 1
1 source rowRow 1 · 2018-03-08 · Disposition to issuer · Disposed 5,951.011 · Balance 0 F1: Includes 454.9542 shares acquired under the Company's Employee Stock Purchase Plan on March 6, 2018. F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-08 · Disposition to issuer · Disposed 14,230 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-03-08 · Disposition to issuer · Disposed 42,727 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51 | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-03-08 · Disposition to issuer · Disposed 113,230 · Balance 0 F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51 | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-03-08 · Disposition to issuer · Disposed 56,615 · Balance 0 F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 454.9542 shares acquired under the Company's Employee Stock Purchase Plan on March 6, 2018.
F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash.
F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock.
F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.
F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.
Discover Financial Services
Report date May 18, 2025 · Filed May 19, 2025
Section 16 reporting ended · disclosed 2025-05-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-05-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-05-18 · Disposition to issuer · Disposed 79,943 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 19, 2024, by and among the Issuer, Capital One Financial Corporation ("Capital One"), and Vega Merger Sub, Inc. ("Merger Sub") (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time") between the Issuer and Merger Sub (the "Merger"), each share of Issuer common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive 1.0192 shares of Capital One common stock (the "Exchange Ratio"). The Merger closed on May 18, 2025 (the "Closing Date"). The closing price of Capital One common stock on the New York Stock Exchange on the last trading day prior to the Closing Date was $197.22. All fractional shares were paid in cash. F2: Includes 42,023 shares of Issuer common stock in respect of restricted stock unit awards (the "Issuer RSU Awards"). Pursuant to the Merger Agreement, at the Effective Time, each Issuer RSU Award outstanding immediately prior to the Effective Time was converted into a Capital One restricted stock unit award in respect of that number of shares of Capital One common stock (rounded to the nearest whole share) equal to the product of (i) the total number of shares of Issuer common stock subject to the Issuer RSU Award immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, and which is otherwise be subject to the same terms and conditions as applied to the corresponding Issuer RSU Award immediately prior to the Effective Time. F3: Includes 77.4 shares of Issuer common stock acquired under the Discover Financial Services Employee Stock Purchase Plan for the periods beginning January 1, 2025 and ending March 31, 2025 and beginning April 1, 2025 and ending May 5, 2025. F4: As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any shares of Issuer common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 19, 2024, by and among the Issuer, Capital One Financial Corporation ("Capital One"), and Vega Merger Sub, Inc. ("Merger Sub") (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time") between the Issuer and Merger Sub (the "Merger"), each share of Issuer common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive 1.0192 shares of Capital One common stock (the "Exchange Ratio"). The Merger closed on May 18, 2025 (the "Closing Date"). The closing price of Capital One common stock on the New York Stock Exchange on the last trading day prior to the Closing Date was $197.22. All fractional shares were paid in cash.
F2: Includes 42,023 shares of Issuer common stock in respect of restricted stock unit awards (the "Issuer RSU Awards"). Pursuant to the Merger Agreement, at the Effective Time, each Issuer RSU Award outstanding immediately prior to the Effective Time was converted into a Capital One restricted stock unit award in respect of that number of shares of Capital One common stock (rounded to the nearest whole share) equal to the product of (i) the total number of shares of Issuer common stock subject to the Issuer RSU Award immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, and which is otherwise be subject to the same terms and conditions as applied to the corresponding Issuer RSU Award immediately prior to the Effective Time.
F3: Includes 77.4 shares of Issuer common stock acquired under the Discover Financial Services Employee Stock Purchase Plan for the periods beginning January 1, 2025 and ending March 31, 2025 and beginning April 1, 2025 and ending May 5, 2025.
F4: As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any shares of Issuer common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2017 Filed Mar 27, 2017 20:31 UTC Amendment | Bioverativ Inc. BIVV · Entity 168487 | GrantNon-Qualified Stock Option · Derivative | 56,615 | $0.00 Strike: $44.51 | $0.00 |
DisclosureSEC source: 0001127602-17-012955 · form4a.xml · derivative · entry 1 Greene John · CIK 0001610732 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,615 Underlying: Common Stock · 56,615 shares Expires 2027-02-14 F1 · shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. F2 · derivative.exercise_date: This option vests in three equal annual installments beginning on February 14, 2018. F1 · derivative.underlying_shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. F1 · balance_after: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.